July 27, 2020

Jonathan W. Friedberg, MD, MMSc, has been appointed as the next editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO).

July 20, 2020

ASCO and ACCC today announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer.

July 17, 2020

The Association of Clinical Oncology congratulates the eighteen practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second quarter of 2020.

June 25, 2020

Nancy R. Daly, MS, MPH, has been named Chief Executive Officer of Conquer Cancer, the American Society of Clinical Oncology (ASCO) Foundation, a move that reflects Ms. Daly’s growing leadership of the organization and successful expansion of its research grants and awards program.

June 10, 2020

On June 10, ASCO’s CancerLinQ® launched the SmartLinQQOPI® Certification Pathway, an application that empowers oncology practices to automate quality measure tracking and reporting for participation in ASCO’s Quality Oncology Practice Initiative (QOPI) Certification Program, a three-year certification recognizing practices’ commitment to high-quality care for outpatient oncology practices.

June 4, 2020

On June 4 the American Society of Clinical Oncology announced record-breaking attendance at its three-day virtual scientific meeting, held online from Friday, May 29, through Sunday, May 31. More than 42,700 attendees from 138 countries have participated thus far, learning virtually about new clinical cancer advances in every area of cancer research.


May 29, 2020

On May 29, ASCO’s CancerLinQ® announced that it launched a new platform for CancerLinQ Discovery®, its de-identified real-world cancer data product for researchers across the cancer community. 

May 29, 2020

Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study provide real world evidence to support recent clinical trial data that demonstrate a role for olaparib (Lynparza) in the treatment of advanced prostate and pancreatic cancers with BRCA1/2 inactivating mutations.

May 28, 2020

Conquer Cancer, the ASCO Foundation, is honored to announce the recipients of its awards supporting researchers with projects spanning many areas in cancer care, including immunotherapy, lung, breast cancer, and palliative care.

May 28, 2020

Researchers have developed an algorithm to identify molecular targets and pair them with targeted therapies for relapsed pediatric cancers with a poor prognosis. In a recent study, this approach extended the time until disease progression by three months for a small group of pediatric patients with very high-priority targets.

May 28, 2020

ALEXANDRIA, Va. — In a small, phase II study of a very rare cancer that develops inside a woman’s uterus during or after pregnancy, treatment with avelumab (Bavencio) potentially cured 8 out of 15 women with cancer that was resistant to single-agent chemotherapy. This is the first trial exploring use of immunotherapy in patients with gestational trophoblastic tumors (GTT) and suggests that avelumab may be a new therapeutic option for these patients. The results will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. 

May 28, 2020

Treatment with avelumab combined with best supportive care following chemotherapy significantly extended overall survival compared with best supportive care alone in patients with advanced urothelial cancer in the JAVELIN Bladder 100 trial.

May 28, 2020

EGFR) mutation significantly improved disease-free survival in a phase III study. Of patients with stage II-IIIA NSCLC who received osimertinib, 90% were alive at two years without the cancer recurring, compared with 44% who received a placebo. In stage II-IIIA patients, the risk of disease recurrence or death was reduced by 83% for patients treated with adjuvant osimertinib after surgery compared to placebo.

May 28, 2020

ALEXANDRIA, Va. — Front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival vs chemotherapy in patients with a type of advanced colorectal cancer that has a high number of mutations, which previous research suggests may have a poor prognosis for some patients. This is the first time pembrolizumab has been shown to benefit these patients when used as a front-line therapy. The findings come from an interim analysis of the phase III KEYNOTE-177 trial that will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 28, 2020

ALEXANDRIA, Va. — In patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death, according to an analysis of 928 patients. COVID-19 treatment with both hydroxychloroquine and azithromycin was also strongly associated with increased risk of death, according to data from the COVID-19 and Cancer Consortium (CCC19) registry. The registry contains data from patients who have tested positive for COVID-19 and around 40% of patients in the registry also have active cancer. The data will be presented as part of the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.